These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15608529)

  • 1. Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras.
    Galai N; Vlahov D; Bareta JC; Wang C; Cohn S; Sterling TR
    J Acquir Immune Defic Syndr; 2005 Jan; 38(1):74-81. PubMed ID: 15608529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
    Wood E; Hogg RS; Lima VD; Kerr T; Yip B; Marshall BD; Montaner JS
    JAMA; 2008 Aug; 300(5):550-4. PubMed ID: 18677027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
    Celentano DD; Galai N; Sethi AK; Shah NG; Strathdee SA; Vlahov D; Gallant JE
    AIDS; 2001 Sep; 15(13):1707-15. PubMed ID: 11546947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
    Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
    Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection.
    Vlahov D; Galai N; Safaeian M; Galea S; Kirk GD; Lucas GM; Sterling TR
    Am J Epidemiol; 2005 Jun; 161(11):999-1012. PubMed ID: 15901620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008.
    Mehta SH; Kirk GD; Astemborski J; Galai N; Celentano DD
    Clin Infect Dis; 2010 Jun; 50(12):1664-71. PubMed ID: 20450418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users.
    Fu TC; Westergaard RP; Lau B; Celentano DD; Vlahov D; Mehta SH; Kirk GD
    AIDS; 2012 Nov; 26(18):2383-91. PubMed ID: 23079804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors.
    Knowlton AR; Arnsten JH; Eldred LJ; Wilkinson JD; Shade SB; Bohnert AS; Yang C; Wissow LS; Purcell DW
    AIDS Patient Care STDS; 2010 Jul; 24(7):421-8. PubMed ID: 20578910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.
    Mehta SH; Lucas G; Astemborski J; Kirk GD; Vlahov D; Galai N
    AIDS Care; 2007 May; 19(5):637-45. PubMed ID: 17505924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.
    Mocroft A; Madge S; Johnson AM; Lazzarin A; Clumeck N; Goebel FD; Viard JP; Gatell J; Blaxhult A; Lundgren JD
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):369-78. PubMed ID: 10634199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.